Mintz advised biotechnology company NexImmune, Inc. in connection with its upsized $126.5 million initial public offering (IPO) of common stock. Shares debuted on the Nasdaq Global Market on February 12, 2021 under the symbol “NEXI.”
NexImmune, based in Gaithersburg, Maryland, is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body’s own T cells to generate a specific, potent and durable immune response that mimics natural biology.
The Mintz team that advised NexImmune in its IPO was led by Members John T. Rudy and Matthew T. Simpson. The team also included Members David R. Lagasse and Joanne S. Hawana, Of Counsel Benjamin M. Zegarelli, and Associates Andrew R. Pearce, Michelle Choi, Stefano A. Wach, and Ilse P. Johnson.